Latest Biotech News

The Allen Institute released the Brain Knowledge Platform (BKP), an open database aggregating and standardizing datasets from more than 34 million brain cells across 22 species and coupling them...

Day One Biopharmaceuticals agreed to acquire Mersana Therapeutics for $129 million upfront with additional contingent payments that lift the deal value to as much as $285 million, centered on...

Korro Bio announced substantial workforce reductions and a strategic pivot after its RNA‑editing lead program failed to meet potency expectations in early testing. The company said it will cut...

Cellarity published a framework in Nature Communications outlining an integrated multi‑omics and AI approach to predict drug‑induced liver injury (DILI). The company combined transcriptomics,...

The FDA appointed Richard Pazdur—longtime head of the agency’s oncology office—to lead the Center for Drug Evaluation and Research (CDER). The move follows recent leadership turbulence and is...

Nilo Therapeutics launched with a $101 million Series A to develop therapies that harness neural circuits to restore immune homeostasis. The New York‑based startup—founded by academic leaders in...

Researchers introduced an "ultra‑mild" bisulfite sequencing method (UMBS‑seq) published in Nature Communications that reduces DNA strand damage inherent to traditional bisulfite conversion and...

The FDA announced a formal regulatory approach to speed approval of bespoke, patient‑specific therapies for rare and life‑threatening conditions. Agency officials outlined a “plausible mechanism”...

Novartis reported that GanLum, a ganaplacide‑lumefantrine combination, met its primary endpoint in a Phase 3 trial across sub‑Saharan Africa, hitting cure rates that exceed the World Health...

Uniqure disclosed Phase 1/2 data from its AMT‑130 gene‑therapy program for Huntington disease showing a sustained reduction in disease progression. The intracerebral AAV‑delivered microRNA therapy...

AbbVie is terminating its long‑running R&D partnership with Alphabet’s Calico Labs after 11 years, internal documents and reporting show, and plans workforce reductions tied to the wind‑down. The...

Nilo Therapeutics emerged from academic labs with a $101 million Series A to build therapeutics that modulate neural circuits to restore immune homeostasis. Founders include Columbia’s Charles...

Gate Bioscience closed a $65 million financing to move its proprietary “molecular gate” class of small‑molecule protein degraders toward first‑in‑human studies. The company is developing degraders...

Cellarity unveiled an integrated multi‑omics and AI framework to predict drug‑induced liver injury (DILI), publishing methods and validation data in Nature Communications. The clinical‑stage...

Beacon Biosignals secured $86 million in funding to assemble a large, standardized EEG dataset aimed at powering diagnostics and drug development in neurology and psychiatry. The company will...

Evotec announced a milestone payment after Bristol Myers Squibb accepted an IND derived from their strategic protein‑degradation alliance. The $5 million milestone reflects progress in a...

Gene‑editing heavyweight Metagenomi cut roughly 25% of its workforce — including the CEO — as it refocuses on a preclinical hemophilia A program, the company said in a corporate restructuring...

The FDA sketched a new regulatory approach—the “plausible mechanism” pathway—intended to accelerate approvals for individualized and ultra-rare therapies. Agency officials and authors published...

Novartis reported Phase 3 results showing its combination therapy GanLum (ganaplacide plus lumefantrine) was non-inferior to standard of care in 1,688 patients across sub-Saharan African sites and...

The FDA appointed longtime oncology chief Richard Pazdur as director of the Center for Drug Evaluation and Research, a move the agency framed as stabilizing amid recent leadership turnover....